L Brilli
Overview
Explore the profile of L Brilli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brilli L, Toscano P, Carotenuto F, Di Lonardo S, Di Tommasi P, Magliulo V, et al.
Heliyon
. 2024 Apr;
10(8):e29356.
PMID: 38644898
Landfills play a key role as greenhouse gas (GHGs) emitters, and urgently need assessment and management plans development to swiftly reduce their climate impact. In this context, accurate emission measurements...
2.
Brilli L, Martin R, Argenti G, Bassignana M, Bindi M, Bonet R, et al.
J Environ Manage
. 2023 Mar;
336:117575.
PMID: 36893538
Over the last century, the management of pastoral systems has undergone major changes to meet the livelihood needs of alpine communities. Faced with the changes induced by recent global warming,...
3.
Brilli L, Carotenuto F, Chiesi M, Fiorillo E, Genesio L, Magno R, et al.
Sci Total Environ
. 2022 Jun;
842:156843.
PMID: 35750179
Urban afforestation is considered a promising nature-climate solution that may contribute to achieve climate neutrality by 2050, since it can increase C-storage and C-sequestration, whilst providing further multiple ecosystem services...
4.
Brilli L, Danielli R, Campanile M, Secchi C, Ciuoli C, Calabro L, et al.
J Endocrinol Invest
. 2020 Dec;
44(8):1719-1726.
PMID: 33367977
Purpose: Immunotherapy against immune checkpoints has significantly improved survival both in metastatic and adjuvant setting in several types of cancers. Thyroid dysfunction is the most common endocrine adverse event reported....
5.
Forleo R, Fralassi N, Maino F, Capezzone M, Brilli L, Pilli T, et al.
J Endocrinol Invest
. 2020 May;
44(1):139-144.
PMID: 32388842
Purpose: We speculated that radioiodine remnant ablation (RRA) could be performed less frequently in differentiated thyroid cancer (DTC) patients, if the recommendations of the 2018 Italian Consensus (ITA) were applied...
6.
Capezzone M, Secchi C, Fralassi N, Cantara S, Brilli L, Ciuoli C, et al.
J Endocrinol Invest
. 2019 Mar;
42(10):1205-1213.
PMID: 30927240
Purpose: An increased aggressiveness of familial papillary thyroid carcinoma (FPTC) compared with sporadic form has been reported. On the contrary, the biological behavior of familial microPTC (FmPTC) is still debated....
7.
Castagna M, Forleo R, Maino F, Fralassi N, Barbato F, Palmitesta P, et al.
J Endocrinol Invest
. 2018 Feb;
41(9):1029-1035.
PMID: 29470826
Purpose: According to American Thyroid Association (ATA) guideline, papillary thyroid cancer (PTC) with minimal extrathyroidal extension (mETE) is classified at "intermediate risk" of persistent/recurrent disease. However, the impact of mETE...
8.
Pacini F, Castagna M, Brilli L, Pentheroudakis G
Ann Oncol
. 2012 Sep;
23 Suppl 7:vii110-9.
PMID: 22997443
No abstract available.
9.
Pacini F, Castagna M, Brilli L, Pentheroudakis G
Ann Oncol
. 2010 Jun;
21 Suppl 5:v214-9.
PMID: 20555084
No abstract available.
10.
Pacini F, Brilli L, Marchisotta S
Q J Nucl Med Mol Imaging
. 2009 Nov;
53(5):520-5.
PMID: 19910905
The majority of differentiated thyroid carcinomas (DTCs) of follicular cell origin are cured with adequate surgical management and radioiodine therapy. Other thyroid malignancies such as medullary thyroid carcinoma (MTC) or...